Associate Director, US Pricing Strategy Cell Therapy at Bristol-Myers Squibb

Madison, New Jersey, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

BA/BS degree required
Advanced degree in Finance, Economics, Health Economics or a similar discipline is a plus

Responsibilities

Develops and maintains a comprehensive, value-creating pricing strategy for Cell therapy brands, ensuring they maintain strategic prominence with the customer in line with overall brand strategy
Responsible for tracking and communicating competitive activities, as well as changes in the marketplace and the regulatory environment that impact pricing strategies
Works with Cell therapy brand access team & US contracting team to develop & lead comprehensive Gross to Net (GTN) strategies over the life cycle of the molecule, including the launch price, list price evolution and contracting strategy impact
Works collaboratively with Cell therapy & GTN Finance team, US GTN contracting team to assess and communicate Budget, LTFP and Monthly / Quarterly close GTN evolution and variance
Utilizes sophisticated analytics and strong financial acumen to evaluate impact of pricing scenarios on volume/revenue
Partners with the US policy team to assess impact of IRA and other potential policy changes on CAR-T short-, mid- and long-term pricing & access
Leverages provider & payer reimbursement data and analytics and delivers comprehensive provider CAR-T economic across channel, with quarterly report communicated and shared to the Access Marketing, Trade and Payer team
Initiates market research activities in support of pricing strategy and develops standardized methodologies and approaches for analyzing tiered pricing models, conducting pricing sensitivity analysis, and segmenting payers
Works successfully across the matrix to balance the needs of and input from multiple stakeholders (e.g., the brand, Finance, Federal and Policy teams, Trade, HEOR, payer marketing, etc.) who may influence the ultimate pricing/contracting decision
Partners with the HEOR to ensure pricing strategies leverage and consider real world evidence

Skills

Pricing Strategy

Cell Therapy

HEOR

Financial Analysis

Market Analysis

Access Strategy

Strategic Planning

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free